These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 25586096

  • 1. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
    Kaynar M, Yildirim ME, Gul M, Kilic O, Ceylan K, Goktas S.
    Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
    [Abstract] [Full Text] [Related]

  • 2. Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.
    Zhang JY, Ge P, Zhang PY, Zhao M, Ren L.
    Clin Lab; 2019 May 01; 65(5):. PubMed ID: 31115239
    [Abstract] [Full Text] [Related]

  • 3. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer.
    Yuksel OH, Urkmez A, Akan S, Yldirim C, Verit A.
    Asian Pac J Cancer Prev; 2015 May 01; 16(15):6407-12. PubMed ID: 26434851
    [Abstract] [Full Text] [Related]

  • 4. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
    Chen ZD, Wei SM, Cai SL.
    Zhonghua Wai Ke Za Zhi; 2004 May 22; 42(10):593-5. PubMed ID: 15265401
    [Abstract] [Full Text] [Related]

  • 5. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP, Heyns CF, Zarrabi AD.
    BJU Int; 2012 Apr 22; 109(8):1194-7. PubMed ID: 21851551
    [Abstract] [Full Text] [Related]

  • 6. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
    Caglayan V, Onen E, Avci S, Sambel M, Kilic M, Oner S, Aydos MM, Yıldız HE.
    Arch Ital Urol Androl; 2019 Jan 17; 90(4):270-275. PubMed ID: 30655640
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
    Fu S, Zhang X, Niu Y, Wang RT.
    Asian Pac J Cancer Prev; 2018 Mar 27; 19(3):699-702. PubMed ID: 29580043
    [Abstract] [Full Text] [Related]

  • 16. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 17. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H, Kazerouni F, Sanadizade M, Sanadizade J, Kamalian N, Jalali M, Rahbar K, Karimi K.
    Urol J; 2010 Jun 10; 7(2):99-104. PubMed ID: 20535696
    [Abstract] [Full Text] [Related]

  • 18. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF, Guimarães FL, Cabral WL, Salles PG, Mateo EC, Nogueira e Nogueira LM, Fonseca CE, Gomes KB.
    Genet Mol Res; 2015 Oct 28; 14(4):13519-31. PubMed ID: 26535666
    [Abstract] [Full Text] [Related]

  • 19. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
    Wolff JM, Boeckmann W, Borchers H, Handt S, Reineke T, Jakse G.
    Urol Int; 1996 Oct 28; 57(3):170-4. PubMed ID: 8912446
    [Abstract] [Full Text] [Related]

  • 20. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer].
    Semjonow A, Hamm M, Rathert P.
    Urologe A; 1993 May 28; 32(3):250-3. PubMed ID: 7685557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.